Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The main aim of this clinical trial is to find a way of giving ch14.18/CHO, in combination
with subcutaneous aldesleukin (IL-2) and oral isotretinoin (13-cis-RA), to children and young
people with primary refractory or relapsed neuroblastoma without intravenous morphine.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
St. Anna Kinderkrebsforschung
Collaborators:
Alder Hey Children's NHS Foundation Trust Centre Leon Berard Children's University Hospital, Ireland Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Fondazione IRCCS Istituto Nazionale dei Tumori, Milano Great Ormond Street Hospital for Children NHS Foundation Trust Gustave Roussy, Cancer Campus, Grand Paris Hospital Infantil Universitario Niño Jesús, Madrid, Spain Hospital Universitario La Fe Institut Curie Istituto Giannina Gaslini Jena University Hospital Johann Wolfgang Goethe University Hospital Medical University Innsbruck Medical University of Graz Newcastle-upon-Tyne Hospitals NHS Trust NHS Greater Glasgow and Clyde Schneider Children's Medical Center, Israel St. Anna Children's Hospital, Vienna The Leeds Teaching Hospitals NHS Trust University Hospital Southampton NHS Foundation Trust University Hospital Tuebingen University Hospital, Toulouse University Hospitals Bristol and Weston NHS Foundation Trust University Medicine Greifswald